

Powering the Next Generation of Targeted Protein Degraders: Experience-Driven Acceleration

Targeted protein degradation is an innovative strategy that directly removes disease-related proteins, overcoming limitations of traditional inhibitors.

Our expertise spans different modalities of protein degraders, including Proteolysis-targeting chimeras (PROTACs) and Molecular glues.

Proven Expertise & Track Record

188,000+

compounds synthesized

10+

molecules entering late phase

38

IND projects completed since 2023


Supporting 37% of the global clinical protein degrader pipeline,

51% of molecules use both API and Drug Product services


Comprehensive Capabilities

- Synthesis of 350+ common E3-Ligase ligands and linkers
 - VHL, CRBN, cIAP, etc.
 - PEG, alkyl, clickable and rigid linkers, etc.
- Customized synthesis of targeted protein degrader: from mg to kg GMP scale

[Case Study] PROTAC: IND-Ready in 12 Months



Why Partner with Us?



Utilize an integrated CRDMO platform to accelerate drug development from discovery to commercialization



chemistry.wuxiapptec.com

Adhere to the highest quality standards to support the global launch of new drugs

Deliver cost-effective solutions through global scale and technology enablement